Chief Executive Officer
Isaac Bright is co-founder and CEO of RubrYc Therapeutics, leveraging more than 15 years of experience as a physician-entrepreneur to realize our vision and lead our operations. Before joining RubrYc, Isaac was both an operating executive and an accomplished investor in companies (startups through Fortune 500) throughout life science sectors. He launched RubrYc to create novel medicines for patients in need. Isaac earned his B.A. in Biochemistry from Pepperdine University, his MD from the Stanford University School of Medicine, and his MBA as a Howard E. Mitchell Fellow at The Wharton School.
Fun Fact: Isaac was the first in his family to graduate from college & “Finish a Marathon” is no longer on Isaac’s bucket list.
Chief Technology Officer
Matthew Greving is co-founder and Chief Technology Officer at RubrYc Therapeutics. Matt is driven by a passion to utilize the power of integrated computation and laboratory discovery to solve difficult problems in human health. He co-founded RubrYc to pursue this passion and act on his belief that we are at the very early stage of computation-laboratory integration in biological discovery. Growing up on a farm too far to visit friends, Matt developed a love for programming at age 12 with a Commodore 64 computer writing simple programs in his bedroom. He left the farm for undergraduate study in Computer Science and worked as a Software Engineer for 8 years. At that time, he pursued his passion for integrated biological-computational research and received a Ph.D. in Biochemistry. After receiving his Ph.D., he spent the last 16 years applying his biological and computational experience in drug discovery and diagnostics, primarily in early R&D environments of startups.
Fun Fact: Matt was a competitive skydiver before being introduced to alpine rock & ice climbing. He particularly loves climbing the mountains in the Alaska and Himalaya ranges.
Chief Science Officer
Ramesh Baliga, Ph.D. is Chief Science Officer at Rubryc Therapeutics. He brings more than 20 years of experience with increasing levels of responsibility at Bay Area biotech startup companies including IGM Biosciences, Sutro Biopharma, Catalyst Biosciences, and Cytokinetics. He is passionate about building and refining platforms and teams to produce clinical candidates for patients in need. Before starting his biotech career, Ramesh earned his Masters in Organic Chemistry from the Indian Institute of Technology, Mumbai, his Ph.D. in Bioorganic Chemistry at Caltech, and completed postdoctoral training at Yale University. He is an author on numerous foundational patents and publications.
Fun fact: Ramesh’s proudest accomplishments are earning his first degree black-belt in Shotokan Karate and his first (and last!) tandem skydive. He likes to relax by grilling on his kamado grill while drinking his favorite IPA and listening to jazz on vinyl.
Olga Monterrosa is the Executive Administrator at RubrYc Therapeutics. Olga brings 6 years of experience in business development and operations. Before joining RubrYc Therapeutics, Olga worked for a local startup franchise based business and was instrumental in helping them grow from 3 locations to 50 nation wide, within 3 years. Olga studied the English and Spanish Languages at State University in Ukraine and when she moved to the US, she furthered her education by completing a top tier Web Development Bootcamp.
Fun Fact: Olga was born and raised in Ukraine and moved to the US at a young age by herself. She enjoys reading, spending time with her family, and weekend trips to new places.
Machine Learning Scientist
Alex Taguchi is RubrYc's Machine Learning Scientist, who is in charge of researching, building, and implementing artificial intelligence for antibody drug discovery. He has authored more than 20 peer-reviewed scientific publications in protein computational biology. Alex attained dual Physics (B.S.) and Japanese (B.A.) degrees from the University of California San Diego, and his Ph.D. in Biophysics from the University of Illinois Urbana-Champaign. He was a National Institutes of Health postdoctoral fellow at the Massachusetts Institute of Technology before joining the team at RubrYc Therapeutics.
Fun Fact: Alex can do a backflip with a high likelihood of not landing on his face.
Senior Research Associate
Piotr is a Senior Research Associate at RubrYc Therapeutics who brings 4 years of industry experience. Piotr previously worked at Verseon, where he focused on in vitro assays, in vivo animal work, and laboratory maintenance. Piotr’s strength is his adaptability and he joined Rubryc to make a profound and lasting impact in a new and growing company. He holds a Bachelor’s degree in Biochemistry – Molecular Biology from University of California, Santa Barbara.
Fun fact: Piotr enjoys mountain biking and watching bad movies.
Phung Gip is Director of Biology at Rubryc Therapeutics. For more than 10 years, she has been committed to developing novel and transformative therapies for regenerative medicine, cancer, and autoimmune diseases. Phung achieved her Ph.D in Molecular and Cellular Biology at the University of California Berkeley, and completed her postdoctoral fellowship in immuno-oncology at Stanford University. Prior to Rubryc, she led discovery and pre-clinical programs at start-ups focused on biologics for tissue regeneration and cancer immunotherapy.
Fun fact: Phung met Francis Ford Coppola at his 70th birthday party in Napa Valley. Also, she has ridden a camel through the Sahara Desert in Morocco.
Cody Moore is a Scientist II at RubrYc Therapeutics. After receiving a master’s in Biochemistry from Arizona State University, he focused on creating high-throughput assays and analytics for diagnostics applications at HealthTell. This focus has shifted towards drug discovery with the formation of RubrYc Therapeutics in 2018.
Fun Fact: Cody is a talented musician.
Sr. Scientist, Mammalian Cell Biology
Claire is the Sr. Scientist, Mammalian Cell Biology at RubrYc Therapeutics. She earned her PhD in Biotechnology from the University of Manchester in the UK, which was focused on understanding the cause of expression difficulties of novel format antibodies in mammalian cell platforms. This collaborative project with GlaxoSmithKline marked the beginning of 10 years of experience working at the interface between academia and industry. She held positions both in biotech startups and in academia, with a focus on biotherapeutics. Most recently she completed her post-doctoral at the Manchester Institute of Biotechnology working with two industrial partners to characterize CRISPR engineered CHO cells. Claire’s passion for science has always been driven by her desire to develop medicines that target intractable medical conditions, which perfectly aligned with RubrYc’s exciting and novel approach to drug discovery. She joined the team to be a key contributor to their therapeutic discovery platform.
Fun Fact: Claire grew up on a campsite in France and has loved travel ever since – she has moved house 27 times! In her spare time, Claire enjoys all things creative including writing, painting, crafting and cooking.
Associate Principal Scientist, Machine Learning
Andrew Chang is the Associate Principal, Machine Learning Scientist at RubrYc Therapeutics. He brings in his passion and years of industry expertise to understand protein grammar via high-throughput screening and artificial intelligence. Prior to RubrYc, he helped Synthego establish an active learning framework that improves gene-editing efficiency. Andrew earned his B.S in Physics from the National Taiwan University and Biophysics Ph.D. from the University of Michigan. He attained his post-doctoral training at Genentech, where he has worked on several machine learning and protein engineering projects that later entered clinical trials. Andrew then became a data scientist in Genentech's clinical trial team, working on statistical and deep learning methods for identifying genetic biomarkers.
Fun Fact: Andrew previously learned a hard lesson in trying to predict cryptocurrency. He then decided to dedicate 100% of his computation resource to DNA and Amino Acids
Director, Antibody Engineering
Jianhui Zhou, Ph.D. is Director of Antibody Engineering at RubrYc Therapeutics. He brings more than 20 years of experience in antibody discovery, engineering, and bispecific antibody development from the Bay Area Research Institute and biotech companies including Children’s Hospital Oakland Research Institute, Genentech, Immune-Onc Therapeutics, and CS Bay Therapeutics. He is passionate about engineering the best-in-class bispecific antibodies/fusion proteins for cancer therapy and for autoimmune diseases. Jianhui completed his Ph.D in Molecular and Cell Biology at Pennsylvania State University at University Park and his postdoctoral research at University of California Berkeley.
Fun fact: Jianhui enjoys outdoor activities such as hiking and camping.
Associate Principal Scientist, Discovery Biology
Janica Wong brings expertise of pre-clinical experience in immune-oncology, stem cell biology, and metabolism. Prior to joining RubrYc, her work at Merck focused on multi-omics profiling of human samples and primary human tissue-based assays in discovery oncology. She received her Bachelor’s degree in Biochemistry and Masters in Physiology in the Chinese University of Hong Kong. Later, she continued to earn her Ph.D. at the Nevada Cancer Institute and Roseman University, mentored by Dr. Fiscus, whose work in nitric oxide with Dr. Murad led to the Nobel Prize in 1998. She completed her postdoctoral training at Stanford University studying adult stem cell fate.
Fun fact: Outside the lab, Janica enjoys teaching yoga to fellow scientists to “zen out”. She is also a geek for Broadway musicals and classical music, where she played the clarinet, violin, and piano since she was a kid.
Bill W. Colston, PhD
Executive Chairman, Board of Directors
Dr. Colston started his career at Lawrence Livermore National Laboratory (LLNL), where he helped build one of the largest civilian biodefense programs in the country. He left LLNL in 2008 to found a new company, QuantaLife Inc., where he and his team developed a highly accurate genetic analysis system called Droplet Digital PCR. QuantaLife grew exponentially during his tenure as CEO and was sold to BioRad in 2011. Shortly after his departure from BioRad, Dr. Colston helped found a new life sciences company, HealthTell Inc. This exciting new venture has created a powerful new test for profiling an individual’s immune status and has formed partnerships to enable a new generation of diagnostics and therapies. A prolific scientific writer and inventor, Dr. Colston sits on the Board of Directors for HealthTell, Rheonix, and Purigen Biosystems.
Mohan Srinivasan, Ph.D., was the Co-Founder and VP, Discovery R&D for RubrYc’s first year operating.